February 26, 2020 10:23 AM EST
Deals
Cell/Gene Tx

Will a 'risk-of­f' mind­set has­ten cell ther­a­py M&A? Io­vance surges on buy­out chat­ter

Amber Tong

Is it time for some cell ther­a­py M&A?

In­vestors of Io­vance Bio­ther­a­peu­tics cer­tain­ly thought so, send­ing its stock $IO­VA up as much as 40% af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

US with­draw­al from WHO could jeop­ar­dize in­for­ma­tion shar­ing

J&J’s Spra­va­to hit $1B in rev­enue in 2024

In­hi­brx’s ear­ly col­orec­tal can­cer da­ta cloud­ed by pa­tient death

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times